Nyrada raises A$12m in placement for Xolatryp Phase IIa
Nyrada (ASX:NYR) raised A$12.0 million via a placement of about 19.4 million CHESS Depositary Instruments (CDIs) priced at A$0.62 per CDI, and will target an additional A$2.0m via a securities purchase plan. Proceeds are for development of lead drug candidate Xolatryp and pipeline expansion.